Full-Time

Commercial Manufacturing & Supply Chain Senior Project Manager

Confirmed live in the last 24 hours

Vertex Pharmaceuticals

Vertex Pharmaceuticals

1,001-5,000 employees

Develops medicines for serious diseases

Compensation Overview

$136.4k - $204.6k/yr

+ Bonus + Equity Awards

Senior

Company Does Not Provide H1B Sponsorship

Boston, MA, USA

This position requires 3 days/week onsite.

Category
Project Management
Operations & Logistics
Business & Strategy
Required Skills
Power BI
Word/Pages/Docs
Excel/Numbers/Sheets
Requirements
  • Bachelor’s degree in engineering, life sciences or related field. Advanced degree (MS, PhD or MBA preferred).
  • A minimum of 6 years of experience in the biopharmaceutical industry.
  • Previous experience in Biologics manufacturing and managing external CDMOs.
  • A minimum of 3 years of experience in project management of biopharmaceutical products
  • Experience interacting with and/or managing CMOs/service providers.
  • Working knowledge of biotechnology, GMPs, and drug development lifecycle.
  • Ability to work effectively in cross-functional, matrixed environment, prioritizing and managing multiple tasks simultaneously, integrating cross-functional issues and balancing competing priorities effectively.
  • Expertise in Microsoft suite (Project, PowerPoint, SharePoint, Word, Excel, Outlook). Experience with other PM tools a plus (e.g. Smartsheet, ThinkCell, Power BI, etc.).
  • Excellent oral and written communication skills, including presentation and facilitation skills, to effectively inform key updates & issues across all levels of the organization.
  • Strong analytical, problem solving and critical thinking skills, including an ability to combine attention to detail with a big picture perspective.
Responsibilities
  • Partner closely with functional area leads and CDMOs to develop, maintain and actively monitor integrated project plans. Identify/communicate interdependencies as well as critical path activities for the project(s)
  • Track and monitor key milestones and decision points and work with project team members to drive delivery of project objectives
  • Effectively communicate with internal and external team members, and key stakeholders on the status, objectives, risks, and mitigation plans associated with projects
  • Organize and maintain team communications including meeting agendas, minutes, decision logs, tasks lists, and risk analyses/mitigation strategies using Program Management preferred technologies
  • Update and maintain project status tools, such as a project action log, risk register, budget and reporting dashboards
  • Assist in the creation and deployment of templates to manage team activities
  • Consistently perform duties within established SOPs, and in accordance with GxP requirements, where applicable.
Desired Qualifications
  • Some knowledge and/or experience with cell / gene therapy methodologies and a strong understanding of risk management will be an asset.
  • Experience with regulatory submissions, manufacturing or QC/QA experience a plus.
Vertex Pharmaceuticals

Vertex Pharmaceuticals

View

Vertex Pharmaceuticals develops medicines for serious diseases, focusing on conditions like cystic fibrosis. The company conducts extensive research and development to create new drugs, often collaborating with other biotech firms to enhance its therapeutic offerings. One of its notable products is ivacaftor, which has shown effectiveness in treating cystic fibrosis. Vertex differentiates itself from competitors through its commitment to scientific innovation and strategic partnerships that expand its research capabilities. The goal of Vertex Pharmaceuticals is to improve the quality of life for patients with severe and life-threatening conditions by bringing effective treatments to market.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Boston, Massachusetts

Founded

1989

Simplify Jobs

Simplify's Take

What believers are saying

  • Vertex's EU approval expands its cystic fibrosis treatment market.
  • Partnerships with Arbor and Orna enhance Vertex's gene therapy capabilities.
  • Increased focus on personalized medicine aligns with Vertex's patient-centric approach.

What critics are saying

  • Increased competition in cystic fibrosis could impact Vertex's market share.
  • Regulatory changes in the EU may delay Vertex's drug approvals.
  • High R&D costs and potential trial failures could strain Vertex's finances.

What makes Vertex Pharmaceuticals unique

  • Vertex focuses on transformative medicines for serious diseases, like cystic fibrosis.
  • The company invests heavily in R&D and strategic partnerships for drug development.
  • Vertex's innovative cell and gene therapies set it apart in the biotech industry.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Hybrid Work Options

Company News

Buniversity
May 1st, 2025
VERTEX upset Grayhound for spot at BLAST Showdown

VERTEX locked in a first-place finish at Fortress OCE Masters Fall 2022 Finals in Melbourne to qualify for BLAST Premier Fall Showdown.

BioSpace
Apr 14th, 2025
Vertex Researcher, Paul Negulescu Ph.D., Receives the 2025 Canada Gairdner International Award for Pioneering Research and Discovery of Medicines for Cystic Fibrosis

Vertex researcher, Paul Negulescu Ph.D., receives the 2025 Canada Gairdner International Award for pioneering Research and discovery of medicines for Cystic Fibrosis.

Biz Owner Daily
Apr 7th, 2025
EU Approves Expanded Label for Vertex Pharmaceuticals' Cystic Fibrosis Treatment

Vertex Pharmaceuticals has received approval from the European Union to broaden the label for its cystic fibrosis treatment.

Slater Sentinel
Mar 23rd, 2025
Stevens Capital Management LP Makes New $829,000 Investment in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Stevens Capital Management LP makes new $829,000 investment in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX).

Investing.com
Mar 20th, 2025
BMO maintains Vertex stock Market Perform rating and $41 target

The reaffirmation of the rating and target came after Vertex held its first analyst day since its initial public offering in 2020.